Kala Pharmaceuticals, Inc. announced the appointment of Mark Iwicki as Executive Chairman and a member of its board of directors. Mr. Iwicki will help guide corporate strategy and commercial preparations for Kala's lead product candidate, KPI-121, a novel nanoparticle formulation of loteprednol etabonate in development for the treatment of post-surgical ocular inflammation and pain and for dry eye and meibomian gland disease.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.96 USD | -0.67% |
|
-9.28% | -14.86% |
May. 17 | HC Wainwright Adjusts Kala Pharmaceuticals Price Target to $18 From $21, Maintains Buy Rating | MT |
May. 14 | KALA BIO, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.86% | 16.79M | |
+50.70% | 791B | |
+41.96% | 630B | |
-7.15% | 350B | |
+18.77% | 328B | |
+8.79% | 298B | |
+18.02% | 246B | |
+1.27% | 225B | |
+11.95% | 218B | |
+3.68% | 160B |
- Stock Market
- Equities
- KALA Stock
- News KALA BIO, Inc.
- Kala Pharmaceuticals, Inc. Appoints Mark Iwicki as Executive Chairman and Member of Board of Directors